This article refers to 'Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function' by M.F. Hoes et al., published in this issue on pages 910-919.
However, the observation that iron deficiency is associated with poor exercise capacity and poor outcome, even in the absence of anaemia, underscores the pathophysiologic role in muscular dysfunction. Iron is an essential co-factor in oxidative phosphorylation (OXPHOS) proteins in skeletal muscles and cardiomyocytes, necessary for the high energetic demand of these tissues. The heart, more than any other tissue, requires a tremendous amount of energy, cycling over 6 kg of ATP a day. 5 In order to do so, the heart is equipped with a well streamlined metabolic chain ( Figure 1A ) capable of adapting to changes in the intensity of mechanical work. Fatty acids and glucose are broken down in the beta-oxidation and aerobic glycolysis, respectively, leading to an increase in acetyl coenzyme A being used in the Krebs cycle. Afterwards, the mitochondrial respiratory chain produces ATP by means of OXPHOS. Finally, the ATP is converted to phosphocreatine, which is shuttled to regions of mechanical work. Most energy during systole is required for actin-myosin (un)coupling (contraction), while during diastole most energy is required to buffer cytosolic calcium (relaxation).
In this issue of the Journal, Hoes and colleagues report on an elegant experiment assessing the impact of iron deprivation on mitochondrial function, gene expression and contractility in human embryonic stem cell-derived cardiomyocytes. 6 Using the iron chelator deferoxamine, they induced a state of intracellular iron deficiency (measured as a decreased intracellular ferritin content). Afterwards they noted several interesting observations, all of which are highly relevant and relatable to animal and human data ( Figure 1B) .
Firstly, intracellular iron deficiency resulted in upregulation of the transferrin receptor (TfRC) and other metal ion transporters in an attempt to replenish intracellular iron. This observation corroborates the finding of Melenovsky et al., demonstrating that cardiac explants of patients with end-stage heart failure with the lowest iron content had the highest expression of TfRC. 7 However, it is important to understand that the abundancy of TfRC in the failing myocardium still remains lower than in the healthy myocardium. Indeed, Maeder et al. 8 demonstrated that mainly beta-adrenergic stress in heart failure results in a progressive downregulation of TfRC, inducing cardiac iron deficiency.
Secondly, intracellular iron deficiency resulted in a reduced OXPHOS chain activity affecting basal respiration, ATP synthase-linked respiration and maximal respiration during Seahorse Mito Stress testing. Collectively, this resulted in a 74% lower ATP content after 4 days of deferoxamine incubation, which was driven by a reduced OXPHOS chain activity of complexes I, II and III, which are highly dependent on iron-sulfur clusters for their functioning. This reduced activity of complexes I-III in states of iron deficiency has also been found in both animal and human myocytes. 7, 9 Thirdly, the energetic crisis induced by cardiac iron deficiency resulted in reduced cardiomyocyte systolic and diastolic shortening. This is in line with the elegant experiment of Haddad et al. phosphorylation, which is shuttled to sites of mechanical action. The diastolic and systolic cycling motion of calcium results in contraction and relaxation, and also determines the rate of Krebs cycle and oxidative phosphorylation activity [via mitochondrial calcium uniporter (MCU) uptake], hereby coupling energy metabolism to contraction and relaxation. Heart failure is associated with reduced cardiac energetics, often comparing it to an engine out of fuel. (B) Relevant abnormalities induced by cardiac iron deficiency. The different abnormalities and clinical translation are discussed in the main text. CK, creatine kinase; CS, citrate synthase; DFO, deferoxamine; LDH, lactate dehydrogenase; NCA, sodium-calcium exchanger; NKA, sodium potassium; Oxphos, oxidative phosphorylation; PDH, pyruvate dehydrogenase; RyR2, ryanodine receptor 2; SERCA, sarcoplasmic/endoplasmic reticulum calcium ATPase; TfRC, transferrin receptor.
In conjunction with the reduced activity of citrate synthase (the pace-making enzyme of the Krebs cycle), as illustrated by Melenovsky et al. 7 to reduced exercise capacity witnessed in iron-deficient heart failure.
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Finally, and of utter importance, the abnormalities induced by iron depletion were reversible after administering transferrin bound iron. This is completely in line with the observed benefit of ferric carboxymaltose in HFrEF patients in three randomized controlled trials.
12 Therefore, the results of Hoes and colleagues provide further mechanistic and biologic credence to the observed beneficial effects of intravenous ferric carboxymaltose observed in clinical trials.
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Some limitations, however, need to be recognized. The current study only assesses the role of cardiomyocyte iron deficiency. However, similar findings are postulated in skeletal muscles. 4 Additionally, the current experiment forms an extreme model of cardiomyocyte iron deficiency. Furthermore, it is uncertain how this phenotype correlates with the degree of iron deficiency measured as serum ferritin and serum transferrin saturation in clinical practice. Indeed, intra cardiomyocyte ferritin levels are different from ferritin levels measured in the circulation and it is uncertain how these two correlate. Nevertheless, it needs to be mentioned that human stem cell-derived cardiomyocytes contract at a basal rate of ±35 contractions per minute. As energetic demand increases mainly at higher heart rates to support intensified actin-myosin (un)coupling and calcium cycling, it can be postulated that perhaps less severe forms of cardiac iron deficiency can play a clinical significant role during higher work rates (e.g. exercise).
So, how can we improve cardiac myocyte iron levels in clinical practice? Obviously, administering intravenous iron results in saturation of the circulating transferrin allowing for TfRC-mediated endocytosis. In comparison to intravenous iron, oral iron is not capable of replenishing transferrin in the circulation. 13 Therefore, oral iron is not capable of restoring the iron-deprived tissue with upregulated cell surface TfRC. Furthermore, as predominantly beta-adrenergic stress results in lower expression of TfRC, we should aim at optimizing beta-blocker therapy. 7, 9 Finally, in addition to transferrin-bound iron, also non-transferrin-bound iron uptake can be important. Myocardial L-type calcium channels are one of such pathways of non-transferrin-bound iron uptake. Therefore, blocking these channels with L-type calcium channel blockers (diltiazem and verapamil) might be detrimental. 7, 14 Luckily, heart failure specialists already administer ferric carboxymaltose with a IIa level of evidence. Furthermore, we already uptitrate beta-blocker therapy (level IA) and avoid L-type calcium channel blockers (level III) in patients with HFrEF. 
